# Safety Evaluation of 3K3A-APC in Ischemic Stroke

Study · id `cardio:ct-nct02222714` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02222714](<https://clinicaltrials.gov/study/NCT02222714>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02222714

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT02222714. Randomized; quadruple masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2017-04-18 (actual). Results posted on 2018-11-08.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT02222714, source copy `cardio:ctgov-nct02222714-2018-11-08`, retrieved 2026-10-26)
- Start date: 2014-10 (registry gives no type) (ClinicalTrials.gov record NCT02222714, source copy `cardio:ctgov-nct02222714-2018-11-08`, retrieved 2026-10-26)
- Primary completion: 2017-04-18 (actual) (ClinicalTrials.gov record NCT02222714, source copy `cardio:ctgov-nct02222714-2018-11-08`, retrieved 2026-10-26)
- Completion: 2017-06-29 (actual) (ClinicalTrials.gov record NCT02222714, source copy `cardio:ctgov-nct02222714-2018-11-08`, retrieved 2026-10-26)
- Results first posted: 2018-11-08 (ClinicalTrials.gov record NCT02222714, source copy `cardio:ctgov-nct02222714-2018-11-08`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02222714, source copy `cardio:ctgov-nct02222714-2018-11-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02222714-2018-11-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety Evaluation of 3K3A-APC in Ischemic Stroke
- Acronym: RHAPSODY
- Condition: Ischemic Stroke
- Intervention (Biological): 3K3A-APC
- Intervention (Drug): Placebo
- Lead sponsor: ZZ Biotech, LLC
- Lead sponsor class: INDUSTRY
- Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator class: NIH
- Collaborator: Cedars-Sinai Medical Center
- Collaborator class: OTHER
- Collaborator: Massachusetts General Hospital
- Collaborator class: OTHER
- Collaborator: University of Iowa
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as a collaborator: National Institute of Neurological Disorders and Stroke (`cardio:ninds`)
- Registry lists this organization as a collaborator: Cedars-Sinai Medical Center (`cardio:org-cedars-sinai-medical-center`)
- Registry lists this organization as a collaborator: Massachusetts General Hospital (`cardio:org-massachusetts-general-hospital`)
- Registry lists this organization as a collaborator: University of Iowa (`cardio:org-university-of-iowa`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke (`cardio:pubmed-30450637`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e47a129a0c7c3959e1da844fe96b50140b8a806c9f72a71fe2ff35b8edd506c8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
